Comparison of day 3 and day 5 thyroglobulin results after thyrogen injection in differentiated thyroid cancer patients

Creative Commons License

SAGER S., HATIPOGLU E., GUNES B., ASA S., Uslu L., SÖNMEZOGLU K.

THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, cilt.9, sa.6, ss.177-183, 2018 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 9 Sayı: 6
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1177/2042018818770108
  • Dergi Adı: THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.177-183
  • Anahtar Kelimeler: Thyrogen, thyroglobulin, thyroid cancer, RECOMBINANT HUMAN THYROTROPIN, RADIOIODINE REMNANT ABLATION, LOW-DOSE RADIOIODINE, STIMULATING HORMONE, THYROXINE WITHDRAWAL, SERUM THYROGLOBULIN, RECURRENCE, CARCINOMA, DIAGNOSIS
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Background: It is necessary to stimulate serum thyroid-stimulating hormone (TSH) levels either endogenously by thyroid hormone withdrawal (THW) or exogenously by administration of recombinant human TSH (rhTSH) for radioactive iodine (RAI) therapy. Thyrotropin alfa (Thyrogen) has many advantages over THW. Radiation dose to laboratory staff while drawing blood for tests on the day 5 is one of the disadvantages of preferring Thyrogen. Our aim was to compare day 3 and day 5 blood test results after Thyrogen injections.